Comparative Pharmacology
Head-to-head clinical analysis: KENALOG 40 versus SERVISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG 40 versus SERVISONE.
KENALOG-40 vs SERVISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative properties; suppresses cytokine production, inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes lysosomal membranes.
SERVISONE is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors, modulating gene transcription, and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Intra-articular injection: 10-40 mg for large joints, 5-15 mg for medium joints, 2.5-5 mg for small joints. Intralesional injection: 2.5-5 mg per lesion. Intramuscular injection: 40-80 mg once monthly. Not for IV or subcutaneous use.
10-20 mg orally once daily in the morning; higher doses up to 40 mg daily for severe cases.
None Documented
None Documented
Terminal elimination half-life is approximately 2 to 3 hours after IV administration, but due to the triamcinolone acetonide suspension formulation, the effective half-life following intramuscular or intra-articular administration is prolonged to 2-3 weeks due to slow dissolution from the injection site.
Terminal elimination half-life is 3-4 hours. Clinically, this supports twice-daily dosing for sustained effect.
Primarily hepatic metabolism followed by renal excretion of inactive metabolites. Less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 15-20% of total clearance.
Renal (70-80% as metabolites, 5-10% unchanged); fecal/biliary (15-20%)
Category C
Category C
Corticosteroid
Corticosteroid